Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 1;109(2):371-373.
doi: 10.3324/haematol.2023.283708.

Molecular measurable residual disease: staring at red herrings

Amanda C Winters  1 , Daniel A Pollyea  2
Affiliations
Editorial

Molecular measurable residual disease: staring at red herrings

Amanda C Winters et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A fishy story. According to Murphy et al., inclusion of DNMT3A, TET2, ASXL1, splicing factor genes (SRSF2, SF3B1, U2AF1), and IDH2 mutations (DTASI2) in measurable residual disease quantitation for acute myeloid leukemia may worsen the prognostic value of measurable residual disease in this context. DTASI2 mutations may be akin to red herrings that distract or mislead clinicians in their assessments of true residual disease in acute myeloid leukemia.
See this image and copyright information in PMC

Comment on

References

    1. Short NJ, Zhou S, Fu C, et al. . Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6(12):1890-1899. - PMC - PubMed
    1. Heuser M, Freeman SD, Ossenkoppele GJ, et al. . 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753-2767. - PMC - PubMed
    1. Jongen-Lavrencic M, Grob T, Hanekamp D, et al. . Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189-1199. - PubMed
    1. Murphy T, Zou J, Arruda, et al. . Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia. Haematologica. 2024;109(2):671-675. - PMC - PubMed
    1. Lindsley RC, Mar BG, Mazzola E, et al. . Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367-1376. - PMC - PubMed